ERBB2 and breast cancer: In this chapter we review the concept that endocrine resistance (intrinsic and acquired) as the major obstacle in the clinic to the effective treatment of ER+ HER2/neu negative breast cancer and emphasize the need to mechanistically understand how endocrine resistance develops to SERMs, SERDs, and AIs delivered as single agents or in combination with CDKi’s.